Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Executes the first project for developing and manufacturing a novel anticancer mAb
More than 10,000 scientific publications containing EUDRAGIT
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Subscribe To Our Newsletter & Stay Updated